The CB-1 Receptor Antagonist Rimonabant Modulates the Interaction Between Adipocytes and Pancreatic Beta-Cells in Vitro

 

 Buy Article Permissions and Reprints

Abstract

Background: Adipocytes produce signalling molecules which can act on target cells including pancreatic beta-cells. In previous studies we found adipocytes to directly stimulate insulin secretion and the proliferation of pancreatic beta-cells in vitro. Rimonabant acts as an antagonist at the cannabinoid-1 (CB-1) receptor which is expressed on adipocytes. Rimonabant decreases insulin levels in vivo. This effect can either be explained by improving insulin sensitivity or by effects on beta-cells including the modulation of adipocyte – beta-cell interactions.

Objectives: To test how pre-treatment of primary human adipocytes with rimonabant affects the cross-talk between adipocytes and pancreatic beta-cells in vitro.

Results: Rimonabant had no direct effect on insulin secretion or beta-cell proliferation at a concentration range from 1 nM to 1 μM. This is in line with previous findings showing that in the murine pancreas CB-1 receptors are preferentially expressed on non-beta-cells, while rimonabant is a selective blocker of CB-1 receptors. We found fat-cell conditioned-medium without (FCCM) and after pre-treatment for 24 h with 100 nM rimonabant (FCCM-RB) to induce insulin secretion from primary murine beta-cells to a similar extent. Proliferation of a pancreatic beta-cell line was enhanced by FCCM to 219%, while FCCM-RB inhibited proliferation to 53%. As we previously found Wnt-signalling to mediate effects of adipocytes on beta-cell proliferation we tested the ability of FCCM and FCCM-RB to activate canonical Wnt-signalling in target cells. However, there was no significant difference between the groups: FCCM and FCCM-RB stimulated Wnt reporter gene activity to 181% and 179%, respectively. In addition, there was no significant difference in adiponectin levels between FCCM and FCCM-RB (56.8 vs. 58.1 ng/ml), showing that adiponectin does not mediate the differential effects on beta-cell proliferation by FCCM and FCCM-RB.

Conclusion: Our data show that rimonabant modulates the adipocyte – beta-cell interaction with respect to beta-cell proliferation and indicate that signalling molecules other than adiponectin and components of the Wnt pathway mediate this cross-talk.

References

• 1 Bellocchio L, Cervino C, Pasquali R. et al . The endocannabinoid system and energy metabolism.  J Neuroendocrinol. 2008;  20 850-857
  Google Scholar
• 2 Bensaid M, Gary-Bobo M, Esclangon A. et al . The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.  Mol Pharmacol. 2003;  63 908-914
  Google Scholar
• 3 Bermudez-Silva FJ, Sanchez-Vera I, Suarez J. et al . Role of cannabinoid CB2 receptors in glucose homeostasis in rats.  Eur J Pharmacol. 2007;  565 207-211
  Google Scholar
• 4 Bermudez-Silva FJ, Suarez J, Baixeras E. et al . Presence of functional cannabinoid receptors in human endocrine pancreas.  Diabetologia. 2008;  51 476-487
  Google Scholar
• 5 Bluher M. Adipose tissue dysfunction in obesity.  Exp Clin Endocrinol Diabetes. 2009;  117 241-250
  Google Scholar
• 6 Cavuoto P, McAinch AJ, Hatzinikolas G. et al . The expression of receptors for endocannabinoids in human and rodent skeletal muscle.  Biochem Biophys Res Commun. 2007;  364 105-110
  Google Scholar
• 7 DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.  Diabetes Care. 1991;  14 173-194
  Google Scholar
• 8 Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.  N Engl J Med. 2005;  353 2121-2134
  Google Scholar
• 9 Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A. et al . Human adipocytes secrete mineralocorticoid-releasing factors.  Proc Natl Acad Sci USA. 2003;  100 14211-14216
  Google Scholar
• 10 Erdem G, Dogru T, Tasci I. et al . Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus.  Exp Clin Endocrinol Diabetes. 2008;  116 289-292
  Google Scholar
• 11 Ferrannini E, Camastra S, Gastaldelli A. et al . beta-cell function in obesity: effects of weight loss.  Diabetes. 2004;  53 (S 03) S26-S33
  Google Scholar
• 12 Fischer-Posovszky P, Wabitsch M, Hochberg Z. Endocrinology of adipose tissue – an update.  Horm Metab Res. 2007;  39 314-321
  Google Scholar
• 13 Florez JC, Jablonski KA, Bayley N. et al . TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.  N Engl J Med. 2006;  355 241-250
  Google Scholar
• 14 Fujino T, Asaba H, Kang MJ. et al . Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion.  Proc Natl Acad Sci USA. 2003;  100 229-234
  Google Scholar
• 15 Herder C, Schneitler S, Rathmann W. et al . Low-grade inflammation, obesity, and insulin resistance in adolescents.  J Clin Endocrinol Metab. 2007;  92 4569-4574
  Google Scholar
• 16 Herling AW, Gossel M, Haschke G. et al . CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats.  Am J Physiol Endocrinol Metab. 2007;  293 E826-E832
  Google Scholar
• 17 Herling AW, Kilp S, Elvert R. et al . Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats.  Endocrinology. 2008;  149 2557-2566
  Google Scholar
• 18 Jbilo O, Ravinet-Trillou C, Arnone M. et al . The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.  FASEB J. 2005;  19 1567-1569
  Google Scholar
• 19 Juan-Pico P, Fuentes E, Bermudez-Silva FJ. et al . Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell.  Cell Calcium. 2006;  39 155-162
  Google Scholar
• 20 Kieffer TJ, Heller RS, Leech CA. et al . Leptin suppression of insulin secretion by the activation of ATP-sensitive K+ channels in pancreatic beta-cells.  Diabetes. 1997;  46 1087-1093
  Google Scholar
• 21 Kulkarni RN, Wang ZL, Wang RM. et al . Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice.  J Clin Invest. 1997;  100 2729-2736
  Google Scholar
• 22 Lamounier-Zepter V, Ehrhart-Bornstein M, Karczewski P. et al . Human adipocytes attenuate cardiomyocyte contraction: characterization of an adipocyte-derived negative inotropic activity.  FASEB J. 2006;  20 1653-1659
  Google Scholar
• 23 Lazar MA. Resistin- and Obesity-associated metabolic diseases.  Horm Metab Res. 2007;  39 710-716
  Google Scholar
• 24 Magalang UJ, Cruff JP, Rajappan R. et al . Intermittent hypoxia suppresses adiponectin secretion by adipocytes.  Exp Clin Endocrinol Diabetes. 2009;  117 129-134
  Google Scholar
• 25 Marzi C, Huth C, Kolz M. et al . Variants of the transcription factor 7-like 2 gene (TCF7L2) are strongly associated with type 2 diabetes but not with the metabolic syndrome in the MONICA/KORA surveys.  Horm Metab Res. 2007;  39 46-52
  Google Scholar
• 26 Pi-Sunyer FX, Aronne LJ, Heshmati HM. et al . Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.  JAMA. 2006;  295 761-775
  Google Scholar
• 27 Rakatzi I, Mueller H, Ritzeler O. et al . Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1.  Diabetologia. 2004;  47 249-258
  Google Scholar
• 28 Rulifson IC, Karnik SK, Heiser PW. et al . Wnt signaling regulates pancreatic beta cell proliferation.  Proc Natl Acad Sci USA. 2007;  104 6247-6252
  Google Scholar
• 29 Scheen AJ, Finer N, Hollander P. et al . Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.  Lancet. 2006;  368 1660-1672
  Google Scholar
• 30 Schinner S. Wnt-signalling and the metabolic syndrome.  Horm Metab Res. 2009;  41 159-163
  Google Scholar
• 31 Schinner S, Barthel A, Dellas C. et al . Protein kinase B activity is sufficient to mimic the effect of insulin on glucagon gene transcription.  J Biol Chem. 2005a;  280 7369-7376
  Google Scholar
• 32 Schinner S, Scherbaum WA, Bornstein SR. et al . Molecular mechanisms of insulin resistance.  Diabet Med. 2005b;  22 674-682
  Google Scholar
• 33 Schinner S, Ulgen F, Papewalis C. et al . Regulation of insulin secretion, glucokinase gene transcription and beta cell proliferation by adipocyte-derived Wnt signalling molecules.  Diabetologia. 2008;  51 147-154
  Google Scholar
• 34 Schinner S, Willenberg HS, Krause D. et al . Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway.  Int J Obes (Lond). 2007;  31 864-870
  Google Scholar
• 35 Schinner S, Willenberg HS, Schott M. et al . Pathophysiological aspects of Wnt-signaling in endocrine disease.  Eur J Endocrinol. 2009;  160 731-737
  Google Scholar
• 36 Schott M, Seissler J, Lettmann M. et al . Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination.  J Clin Endocrinol Metab. 2001;  86 4965-4969
  Google Scholar
• 37 Seissler J, Nguyen TB, Aust G. et al . Regulation of the diabetes-associated autoantigen IA-2 in INS-1 pancreatic beta-cells.  Diabetes. 2000;  49 1137-1141
  Google Scholar
• 38 Seufert J. Leptin effects on pancreatic beta-cell gene expression and function.  Diabetes. 2004;  53 (S 01) S152-S158
  Google Scholar
• 39 Van Gaal LF, Rissanen AM, Scheen AJ. et al . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.  Lancet. 2005;  365 1389-1397
  Google Scholar
• 40 Van GL, Pi-Sunyer X, Despres JP. et al . Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.  Diabetes Care. 2008;  31 (S 02) S229-S240
  Google Scholar
• 41 Wolfing B, Neumeier M, Buechler C. et al . Interfering effects of insulin, growth hormone and glucose on adipokine secretion.  Exp Clin Endocrinol Diabetes. 2008;  116 47-52
  Google Scholar

Correspondence

Dr. S. Schinner

Department of Endocrinology

Diabetes and Rheumatology

University Hospital Düsseldorf

Moorenstraße 5

40225 Düsseldorf

Germany

Phone: +49/211/811 7810

Fax: +49/211/811 7860

Email: sven.schinner@uni-duesseldorf.de